MDSM News Medistem Files Patent Application for Stem Cell Therapy to Treat Erectile Dysfunction; Potential Therapy Designed to Reverse Multiple Causes of Erectile Dysfunction and Target $3 Billion Global Market for ED Treatments
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Aug. 4, 2006--Medistem Laboratories, Inc. (OTCBB:MDSM) (FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has filed a patent application with the United States Patent and Trademark Office for a potential stem cell therapy for erectile dysfunction (ED).
Medistem's potential stem cell therapy targets the market for ED drugs and other treatments. According to "Drug Store News," this market is approximately $3 billion per year. Unlike the widely prescribed ED drugs currently in use, Medistem believes the invention could address the underlying physiological causes to restore erectile function, both by inhibiting disease processes as well as through regenerative activity to ameliorate and reverse damage to blood vessels, nerves and related cells.
The number of American men suffering from erectile dysfunction is estimated to be near 30 million, according to the National Institute of Health, with an estimated 100 million patients worldwide.
"This invention is designed to treat the root causes of ED, and hopefully enable patients to restore healthy erectile abilities without having to continue taking medications," said Chris McGuinn, Vice President and Chief Operating Officer of Medistem.
Drugs called phosphodiesterase inhibitors currently dominate the market. Still, many ED sufferers are unresponsive to phosphodiesterase inhibitors, cannot tolerate the adverse side effects, or are otherwise ineligible for treatment due to heart disease and other medical conditions.
Medistem's invention contemplates the use of stem cells to restore erectile function through the treatment of various physical factors, including the regeneration of smooth muscle cells inside the penis, neural regeneration and restoration of endothelial cells lining the inside of blood vessels, and the formation of new blood vessels, among other functions.
Frequency of ED increases with age (source: Harvard School of Public Health, 2003). As the U.S. and world population ages, the percentages of men seeking ED treatment is anticipated to accelerate and spur further growth in this multi-billion dollar marketplace.
The patent application was filed in July of 2006. There can be no assurance that the patent application will be approved, or if approved, that the invention will yield a commercially viable treatment.
About Medistem Laboratories, Inc.
Medistem Laboratories is an innovative biotechnology company committed to the creation, licensing and commercialization of advanced medical therapies based on non-controversial adult stem cells. The Company intends to use adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, which the Company believes to be non-controversial sources of stem cells. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. For more information on Medistem please visit http://www.trilogy-capital.com/tcp/medistem/. To read or download Medistem's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/medistem/factsheet.html. Medistem common stock is traded on the Frankfurt, Germany stock exchange under the symbol S2U.
Cautionary Statement
This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. Certain statements in this release may be "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.
Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.
Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.
These factors are discussed in greater detail in the company's Registration Statement on Form SB-2 and its quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.
